Indeed, nanoparticle-mediated targeted delivery for the in vivo inhibition of AEG-1 is a clinically relevant strategy in the context of HCC, as the payload delivery after intravenous administration is the highest for liver compared to other organs. The gene discussed is MTDH; the disease is hepatocellular carcinoma.